<DOC>
	<DOC>NCT02685345</DOC>
	<brief_summary>The objectives of the study is to evaluate the efficacy and safety of DS-8500a compared with placebo in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin.</brief_summary>
	<brief_title>A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin</brief_title>
	<detailed_description>In patients with type 2 diabetes mellitus being treated with sitagliptin, efficacy and safety of DS-8500a are to be evaluated after 28-day multiple oral administration of DS-8500a at 25 or 75 mg, in a double-blind, placebo-controlled, parallel-group comparison study.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Japanese patients with type 2 diabetes Patients aged ≥ 20 years at the time of informed consent Patients who have been treated with sitagliptin 50 mg monotherapy for the treatment of type 2 diabetes mellitus Patients who have HbA1c ≥ 7.0% and &lt; 9.0% Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis Patients receiving or requiring treatment with insulin Patients with a body mass index (BMI) of &lt; 18.5 kg/m2 or ≥ 35.0 kg/m2 Patients with clinically evident renal impairment (estimated glomerular filtration rate [eGFR] of &lt; 45 mL/min per 1.73 m2) or clinically significant renal disease Patients with fasting plasma glucose ≥ 240 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>adult</keyword>
	<keyword>Phase 2</keyword>
</DOC>